Track GOSS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Gossamer Bio Inc
3115 Merryfield Row, San Diego, CA, United States, 92121
IPO
2019
Employees
161
Industry
Biotechnology
Sector
Healthcare
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 202410
1
Q1 20243-3
0
Q4 20230+1
1
Q2 20231-1
0
4-quarter cumulative
5 sells2 buys
Analyst Ratings
5 analysts covering
Buy60%recommend buy
Buy
3
Hold
2
Sell
0